Sharekhan's research report on PI Industries
Revenue/OPM of Rs. 1,770 crore/24.4%, up 31%/284 bps y-o-y substantially beat our estimate by 10%/147 bps led by robust growth in CSM/domestic business. PAT of Rs. 335 crore (up 46% y-o-y) was 21% above our estimate of Rs. 277 crore. CSM segment’s revenue grew by 29% y-o-y to Rs. 1,278 crores despite high base of last year supported by volume growth of 25% y-o-y and favourable pricing and currency impact of 4% y-o-y. Domestic revenue grew strongly by 36% y-o-y to Rs. 492 crores led by 31%/5% volume/price growth. New brands contributed significantly to domestic revenue growth. Management re-iterated its FY23 revenue growth guidance of over 20% but is conservative given global uncertainties. CSM order book rose sharply by 29% q-o-q to $1.8 bn. The domestic business outlook is promising led by product portfolio expansion and strong demand for existing products. We have increased our FY23-25 earnings estimate to factor higher revenue growth and margin.
Outlook
We maintain a Buy on PI Industries with a revised PT of Rs. 4,200 (reflects upward revision in earnings estimate). A potential acquisition in the pharma space would improve long-term earnings growth outlook and makes us constructive on the stock. At CMP, stock trades at 37x its FY2024E EPS and 32.4x its FY2025E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.